Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Radiopharm Targets Phase 3 Start For RAD101 In Early 2027 After FDA Meeting

RAD: $0.005 +25.00% · MC: $19M

Radiopharm Theranostics says it expects to start a Phase 3 imaging trial of RAD101 in recurrent brain metastases in early 2027, following a successful end-of-Phase 2 meeting with the FDA. The company also reported positive Phase 1 imaging data for RAD301, supporting its planned progression toward Phase 2, and advanced RAD202 to its fourth dosing cohort.

Source announcements: 2026-10-30 16:34 to 2026-10-30 16:34 Sydney time
Story updated 2026-10-30 16:42 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments